APIM-containing Peptide ATX-101 clinical trials
Also written ATX-101.
How each study uses APIM-containing Peptide ATX-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ATX-101
- 11
Studies by the year they started
15 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 2
Kythera Biopharmaceuticals (10) · Allay Therapeutics, Inc. (2) · Aurobac Therapeutics SAS (1) · Northwestern University (1) · THERAPIM PTY LTD (1) · Benjamin Izar (1)
Often tested with
Tested in the same studies.
Moxifloxacin (1) · Carboplatin (1) · Liposomal doxorubicin (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses APIM-containing Peptide ATX-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Phase 2B Study Assessing Pain Relief After Replacement of the KneeCompletedPhase 2Allay Therapeutics, Inc.NCT06799845Written as ATX101
- Phase 1 Single Ascending Dose Study With ATX101CompletedPhase 1Aurobac Therapeutics SASNCT07107802Written as ATX101
- Study Assessing Pain Relief After Replacement of the KneeTerminatedPhase 2Allay Therapeutics, Inc.NCT05260008Written as ATX-101
- Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back FatTerminatedNot applicableNorthwestern UniversityNCT03284034Written as ATX-101
- A Study to Evaluate the Combination of ATX-101 and Platinum-based ChemotherapyTerminatedPhase 1/2THERAPIM PTY LTDNCT04814875Written as ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
- ATX-101 in Advanced Dedifferentiated Liposarcoma and LeiomyosarcomaTerminatedPhase 2Benjamin IzarNCT05116683Written as ATX-101
- Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101CompletedPhase 2Kythera BiopharmaceuticalsNCT02159729Written as ATX-101 (1 mg/cm^2)
- Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of AgeCompletedPhase 3Kythera BiopharmaceuticalsNCT02123134Written as ATX-101
- Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101CompletedPhase 3Kythera BiopharmaceuticalsNCT02163902Written as ATX-101
- To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101CompletedPhase 1Kythera BiopharmaceuticalsNCT01462786Written as ATX-101
- Dose-Escalation Safety and Pharmacokinetic Study of ATX-101CompletedPhase 1Kythera BiopharmaceuticalsNCT00618709Written as ATX-101
- Evaluation of the Effect of ATX-101 on QT/QTc IntervalsCompletedPhase 1Kythera BiopharmaceuticalsNCT01706679Written as ATX-101 (10 mg/ml)
- Open-Label Pharmacokinetic Study of Final Formulations of ATX-101CompletedPhase 1Kythera BiopharmaceuticalsNCT01632917Written as ATX-101 - U.S.
- Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat TissueCompletedPhase 1Kythera BiopharmaceuticalsNCT01319916Written as ATX-101
- A Study to Assess Injection Comfort of Two Formulations of ATX-101CompletedPhase 1Kythera BiopharmaceuticalsNCT01320761Written as ATX-101-BA-free
- ATX-101 AbdominoplastyCompletedPhase 1Kythera BiopharmaceuticalsNCT00835952Written as ATX-101
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
- Phase 2B Study Assessing Pain Relief After Replacement of the KneeOct 19, 2026NCT06799845